Patent 9650442 was granted and assigned to Roche on May, 2017 by the United States Patent and Trademark Office.
The present invention relates to bispecific anti-EGFR/anti IGF-1R antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.